Garrison Bradford & Associates’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Garrison Bradford & Associates’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,147	Closed	-$109K	–	88
2017 Q2	$109K	Hold	11,147	–	–	0.09%	78
2017 Q1	$270K	Buy	11,147 +1,271	+13%	+$31.8K	0.24%	58
2016 Q4	$317K	Sell	9,876 -635	-6%	-$27.1K	0.29%	55
2016 Q3	$525K	Hold	10,511	–	–	0.49%	39
2016 Q2	$446K	Hold	10,511	–	–	0.44%	42
2016 Q1	$692K	Hold	10,511	–	–	0.81%	27
2015 Q4	$653K	Hold	10,511	–	–	0.73%	31
2015 Q3	$704K	Sell	10,511 -1,017	-9%	-$83K	0.78%	29
2015 Q2	$1.12M	Hold	11,528	–	–	1.1%	22
2015 Q1	$1.08M	Hold	11,528	–	–	1.01%	22
2014 Q4	$1.02M	Sell	11,528 -547	-5%	-$39.8K	0.93%	25
2014 Q3	$834K	Sell	12,075 -381	-3%	-$20.4K	0.83%	27
2014 Q2	$714K	Hold	12,456	–	–	0.66%	37
2014 Q1	$494K	Hold	12,456	–	–	0.48%	48
2013 Q4	$522K	Hold	12,456	–	–	0.49%	43
2013 Q3	$371K	Hold	12,456	–	–	0.38%	62
2013 Q2	$661K	Buy	+12,456	New	+$546K	0.71%	35

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Garrison Bradford & Associates's MACK Position: Q3 2017 in Review

Garrison Bradford & Associates sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 11,147 shares — an estimated $109K sold.

Garrison Bradford & Associates first reported a position in MACK in Q2 2013 and held it in 17 quarters. The position peaked at $1.12M in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Garrison Bradford & Associates reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Garrison Bradford & Associates sold 11,147 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $109K.
Garrison Bradford & Associates first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 17 quarters.
Garrison Bradford & Associates's Merrimack Pharmaceuticals, Inc. position peaked at $1.12M in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Garrison Bradford & Associates's 13F filing for Q3 2017, filed 9 Nov 2017.